Antiretroviral therapy for HIV infection in 1997: Updated recommendations of the International AIDS Society-USA panel

Charles C J Carpenter, Margaret A Fischl, Scott M. Hammer, Martin S. Hirsch, Donna M. Jacobsen, David A. Katzenstein, Julio S G Montaner, Douglas D. Richman, Michael S. Saag, Robert T. Schooley, Melanie A. Thompson, Stefano Vella, Patrick G. Yeni, Paul A. Volberding

Research output: Contribution to journalArticle

768 Citations (Scopus)

Abstract

Objective. - To provide current recommendations for antiretroviral therapy for human immunodeficiency virus (HIV) disease. Participants. - The original International AIDS Society-USA 13-member panel representing international expertise in antiretroviral research and care of patients with HIV infection. Evidence. - The following were considered: Newly available clinical and basic science study results, including phase 3 controlled trials; clinical, virological, and immunologic end-point data; interim analyses of studies presented at national and international research conferences; studies of HIV pathophysiology; and expert opinions of panel members. Recommendations were limited to the drugs available in mid 1997. Process. - The full panel met on a regular basis (July 1996, September 1996, November 1996, January 1997, and April 1997) since the publication of its initial recommendations in mid 1996 to review new research reports and interim results. The panel discussed whether and how new information changed its initial recommendations. The recommendations contained herein were determined by group consensus. Conclusions. - New data have provided a stronger rationale for earlier initiation of more aggressive therapy than previously recommended and reinforce the importance of careful selection of initial drug regimen for each patient for optimal long-term clinical benefit and adherence. The plasma viral lead is a crucial element of clinical management for assessing prognosis and the effectiveness of therapy, and such testing must be done properly. Treatment failure is most readily indicated by a rising plasma HIV RNA level and should be confirmed prior to a change of treatment. Therapeutic approaches must be updated as new data, particularly on the long-term clinical effect of aggressive antiretroviral treatment, continue to emerge.

Original languageEnglish
Pages (from-to)1962-1969
Number of pages8
JournalJournal of the American Medical Association
Volume277
Issue number24
StatePublished - Jun 25 1997

Fingerprint

Virus Diseases
HIV
Therapeutics
Expert Testimony
Treatment Failure
Research
Pharmaceutical Preparations
Publications
Patient Care
RNA

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Carpenter, C. C. J., Fischl, M. A., Hammer, S. M., Hirsch, M. S., Jacobsen, D. M., Katzenstein, D. A., ... Volberding, P. A. (1997). Antiretroviral therapy for HIV infection in 1997: Updated recommendations of the International AIDS Society-USA panel. Journal of the American Medical Association, 277(24), 1962-1969.

Antiretroviral therapy for HIV infection in 1997 : Updated recommendations of the International AIDS Society-USA panel. / Carpenter, Charles C J; Fischl, Margaret A; Hammer, Scott M.; Hirsch, Martin S.; Jacobsen, Donna M.; Katzenstein, David A.; Montaner, Julio S G; Richman, Douglas D.; Saag, Michael S.; Schooley, Robert T.; Thompson, Melanie A.; Vella, Stefano; Yeni, Patrick G.; Volberding, Paul A.

In: Journal of the American Medical Association, Vol. 277, No. 24, 25.06.1997, p. 1962-1969.

Research output: Contribution to journalArticle

Carpenter, CCJ, Fischl, MA, Hammer, SM, Hirsch, MS, Jacobsen, DM, Katzenstein, DA, Montaner, JSG, Richman, DD, Saag, MS, Schooley, RT, Thompson, MA, Vella, S, Yeni, PG & Volberding, PA 1997, 'Antiretroviral therapy for HIV infection in 1997: Updated recommendations of the International AIDS Society-USA panel', Journal of the American Medical Association, vol. 277, no. 24, pp. 1962-1969.
Carpenter, Charles C J ; Fischl, Margaret A ; Hammer, Scott M. ; Hirsch, Martin S. ; Jacobsen, Donna M. ; Katzenstein, David A. ; Montaner, Julio S G ; Richman, Douglas D. ; Saag, Michael S. ; Schooley, Robert T. ; Thompson, Melanie A. ; Vella, Stefano ; Yeni, Patrick G. ; Volberding, Paul A. / Antiretroviral therapy for HIV infection in 1997 : Updated recommendations of the International AIDS Society-USA panel. In: Journal of the American Medical Association. 1997 ; Vol. 277, No. 24. pp. 1962-1969.
@article{5510d366771d4988b6783f8e8392cb4a,
title = "Antiretroviral therapy for HIV infection in 1997: Updated recommendations of the International AIDS Society-USA panel",
abstract = "Objective. - To provide current recommendations for antiretroviral therapy for human immunodeficiency virus (HIV) disease. Participants. - The original International AIDS Society-USA 13-member panel representing international expertise in antiretroviral research and care of patients with HIV infection. Evidence. - The following were considered: Newly available clinical and basic science study results, including phase 3 controlled trials; clinical, virological, and immunologic end-point data; interim analyses of studies presented at national and international research conferences; studies of HIV pathophysiology; and expert opinions of panel members. Recommendations were limited to the drugs available in mid 1997. Process. - The full panel met on a regular basis (July 1996, September 1996, November 1996, January 1997, and April 1997) since the publication of its initial recommendations in mid 1996 to review new research reports and interim results. The panel discussed whether and how new information changed its initial recommendations. The recommendations contained herein were determined by group consensus. Conclusions. - New data have provided a stronger rationale for earlier initiation of more aggressive therapy than previously recommended and reinforce the importance of careful selection of initial drug regimen for each patient for optimal long-term clinical benefit and adherence. The plasma viral lead is a crucial element of clinical management for assessing prognosis and the effectiveness of therapy, and such testing must be done properly. Treatment failure is most readily indicated by a rising plasma HIV RNA level and should be confirmed prior to a change of treatment. Therapeutic approaches must be updated as new data, particularly on the long-term clinical effect of aggressive antiretroviral treatment, continue to emerge.",
author = "Carpenter, {Charles C J} and Fischl, {Margaret A} and Hammer, {Scott M.} and Hirsch, {Martin S.} and Jacobsen, {Donna M.} and Katzenstein, {David A.} and Montaner, {Julio S G} and Richman, {Douglas D.} and Saag, {Michael S.} and Schooley, {Robert T.} and Thompson, {Melanie A.} and Stefano Vella and Yeni, {Patrick G.} and Volberding, {Paul A.}",
year = "1997",
month = "6",
day = "25",
language = "English",
volume = "277",
pages = "1962--1969",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "24",

}

TY - JOUR

T1 - Antiretroviral therapy for HIV infection in 1997

T2 - Updated recommendations of the International AIDS Society-USA panel

AU - Carpenter, Charles C J

AU - Fischl, Margaret A

AU - Hammer, Scott M.

AU - Hirsch, Martin S.

AU - Jacobsen, Donna M.

AU - Katzenstein, David A.

AU - Montaner, Julio S G

AU - Richman, Douglas D.

AU - Saag, Michael S.

AU - Schooley, Robert T.

AU - Thompson, Melanie A.

AU - Vella, Stefano

AU - Yeni, Patrick G.

AU - Volberding, Paul A.

PY - 1997/6/25

Y1 - 1997/6/25

N2 - Objective. - To provide current recommendations for antiretroviral therapy for human immunodeficiency virus (HIV) disease. Participants. - The original International AIDS Society-USA 13-member panel representing international expertise in antiretroviral research and care of patients with HIV infection. Evidence. - The following were considered: Newly available clinical and basic science study results, including phase 3 controlled trials; clinical, virological, and immunologic end-point data; interim analyses of studies presented at national and international research conferences; studies of HIV pathophysiology; and expert opinions of panel members. Recommendations were limited to the drugs available in mid 1997. Process. - The full panel met on a regular basis (July 1996, September 1996, November 1996, January 1997, and April 1997) since the publication of its initial recommendations in mid 1996 to review new research reports and interim results. The panel discussed whether and how new information changed its initial recommendations. The recommendations contained herein were determined by group consensus. Conclusions. - New data have provided a stronger rationale for earlier initiation of more aggressive therapy than previously recommended and reinforce the importance of careful selection of initial drug regimen for each patient for optimal long-term clinical benefit and adherence. The plasma viral lead is a crucial element of clinical management for assessing prognosis and the effectiveness of therapy, and such testing must be done properly. Treatment failure is most readily indicated by a rising plasma HIV RNA level and should be confirmed prior to a change of treatment. Therapeutic approaches must be updated as new data, particularly on the long-term clinical effect of aggressive antiretroviral treatment, continue to emerge.

AB - Objective. - To provide current recommendations for antiretroviral therapy for human immunodeficiency virus (HIV) disease. Participants. - The original International AIDS Society-USA 13-member panel representing international expertise in antiretroviral research and care of patients with HIV infection. Evidence. - The following were considered: Newly available clinical and basic science study results, including phase 3 controlled trials; clinical, virological, and immunologic end-point data; interim analyses of studies presented at national and international research conferences; studies of HIV pathophysiology; and expert opinions of panel members. Recommendations were limited to the drugs available in mid 1997. Process. - The full panel met on a regular basis (July 1996, September 1996, November 1996, January 1997, and April 1997) since the publication of its initial recommendations in mid 1996 to review new research reports and interim results. The panel discussed whether and how new information changed its initial recommendations. The recommendations contained herein were determined by group consensus. Conclusions. - New data have provided a stronger rationale for earlier initiation of more aggressive therapy than previously recommended and reinforce the importance of careful selection of initial drug regimen for each patient for optimal long-term clinical benefit and adherence. The plasma viral lead is a crucial element of clinical management for assessing prognosis and the effectiveness of therapy, and such testing must be done properly. Treatment failure is most readily indicated by a rising plasma HIV RNA level and should be confirmed prior to a change of treatment. Therapeutic approaches must be updated as new data, particularly on the long-term clinical effect of aggressive antiretroviral treatment, continue to emerge.

UR - http://www.scopus.com/inward/record.url?scp=0030979361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030979361&partnerID=8YFLogxK

M3 - Article

C2 - 9200638

AN - SCOPUS:0030979361

VL - 277

SP - 1962

EP - 1969

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 24

ER -